96,29 €
0,57 %vorgestern
L&S, 1. Dezember, 22:54 Uhr
ISIN
US0028241000
Symbol
ABT
Berichte

Abbott Laboratories Aktie News

Positiv
Seeking Alpha
7 Tage alt
Abbott Laboratories is a stable investment in challenging times, with an AA- credit rating and a history of surviving economic downturns. ABT has a well-diversified healthcare portfolio, including diagnostics, medical devices, and pharmaceuticals, positioning it to address evolving healthcare challenges. Despite a temporary stock dip, ABT has shown robust financial performance with impressive g...
Positiv
The Motley Fool
13 Tage alt
Ozempic could lead to patients needing to buy fewer interventions for diabetes. It could also do the same for certain cardiovascular interventions.
Neutral
PRNewsWire
20 Tage alt
New data from the ARIES trial show for the first time that an aspirin-free regimen can improve outcomes for people living with the heart pump by reducing hospitalizations without increasing the risk of blood clots More than 30,000 people worldwide have received Abbott's life-saving heart pump to overcome advanced heart failure ABBOTT PARK, Ill., Nov. 13, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) ...
Neutral
Market Watch
23 Tage alt
That's the message from many corporate executives who have lately been peppered with questions about how Wegovy, Ozempic and other drugs widely used for weight loss may impact their bottom line.
Negativ
Finbold
24 Tage alt
Quiver Quantitative, the pioneering company behind an alternative data platform designed for retail investors, has been actively tracking stock market trades made by US Congress members and other political figures. Some of the trades have been notably controversial, mainly due to their timing or because they violated federal laws.
Positiv
The Motley Fool
24 Tage alt
Both Coca-Cola and Abbott Labs have earned the title of Dividend King. That means they have at least a 50-year track record of dividend growth.
Positiv
Reuters
24 Tage alt
Abbott India , the local unit of U.S. healthcare firm Abbott Laboratories , reported a 17.7% rise in second-quarter profit on Thursday, driven by strong sales in its mainstay pharmaceuticals segment.
Positiv
The Motley Fool
25 Tage alt
The rise of weight-loss treatments has some investors worried about demand for certain medical devices. Yet, DexCom and Abbott Labs still see strong sales for their continuous glucose monitoring devices.
Mehr News anzeigen

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen